Regeneron Pharmaceuticals, Inc. balance sheet
At the end of its fiscal year on Dec 31, 2025, Regeneron Pharmaceuticals, Inc. reported total assets of $40.56B and shareholders' equity of $31.26B. That works out to liabilities equal to 23% of assets, a current ratio of 4.13 (current assets ÷ current liabilities), long-term debt of 0.06× shareholders' equity.
Balance sheet at each fiscal year end
| Fiscal year ended | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Total assets | $6.97B | $8.76B | $11.73B | $14.81B | $17.16B | $25.43B | $29.21B | $33.08B | $37.76B | $40.56B |
| Current assets | $3.18B | $4.33B | $6.45B | $7.69B | $9.78B | $14.01B | $15.88B | $19.48B | $18.66B | $18.02B |
| Cash & equivalents | $535.20M | $812.70M | $1.47B | $1.62B | $2.19B | $2.89B | $3.11B | $2.73B | $2.49B | $3.12B |
| Total liabilities | $2.52B | $2.62B | $2.98B | $3.72B | $6.14B | $6.67B | $6.55B | $7.11B | $8.41B | $9.30B |
| Current liabilities | $1.24B | $1.14B | $1.44B | $2.10B | $2.70B | $3.93B | $3.14B | $3.42B | $3.94B | $4.37B |
| Long-term debt | — | — | — | $0 | $1.98B | $1.98B | $1.98B | $1.98B | $1.98B | $1.99B |
| Shareholders' equity | $4.45B | $6.14B | $8.76B | $11.09B | $11.03B | $18.77B | $22.66B | $25.97B | $29.35B | $31.26B |
| Reported in | 10-K 2018 | 10-K 2019 | 10-K 2020 | 10-K 2021 | 10-K 2022 | 10-K 2023 | 10-K 2024 | 10-K 2025 | 10-K 2026 | 10-K 2026 |
Balance-sheet figures are point-in-time values on the last day of each fiscal year. Some companies (for example banks and insurers) do not present current assets and liabilities; those cells show —.
Source: SEC EDGAR XBRL company facts for CIK 872589 (raw data). Most recent filing in this dataset: 10-Q filed Oct 30, 2026. SEC data file dated Nov 3, 2026; page built Nov 5, 2026. Figures are as most recently reported, including restatements. How we select figures.